• Dual Metrics for In Vitro Cancer Drug Response: Insights fro

  2026-05-03

  Schwartz's dissertation critically examines how in vitro measurement strategies—specifically, the distinction between relative and fractional viability—impact the interpretation of anti-cancer drug responses. The work demonstrates that most agents, including HDAC inhibitors like Entinostat (MS-275), simultaneously affect cancer cell proliferation and induce cell death, but in different proportions and with distinct temporal dynamics, emphasizing the importance of nuanced assay selection in preclinical research.

• Cediranib (AZD2171) in Quantitative Angiogenesis: From Pathw

  2026-05-02

  Explore Cediranib (AZD2171) as a next-generation angiogenesis inhibitor for cancer research. This article uniquely emphasizes quantitative assay design and interpretation, grounded in systems-biology insights and the latest in vitro evaluation methodologies.

• Afatinib (BIBW 2992) in Advanced Tumor Assembloid Research

  2026-05-01

  Afatinib (BIBW 2992) empowers oncology researchers to dissect ErbB signaling and resistance mechanisms in physiologically relevant assembloid models. This guide delivers practical setup, protocol optimization, and troubleshooting strategies, directly integrating the latest assembloid innovations to enhance cancer biology research.

• PDK4-IN-1 Hydrochloride: Precision PDK4 Inhibitor for Metabo

  2026-05-01

  PDK4-IN-1 hydrochloride empowers researchers to dissect mitochondrial energy metabolism with nanomolar selectivity, enabling precise control in metabolic, oncological, and cardiac hypertrophy models. Its robust workflow integration and troubleshooting versatility, backed by landmark studies, establish it as a cornerstone for translational metabolic research.

• Lipid Nanoparticle Delivery of ABE8e Edits COL7A1 in DEB Fib

  2026-04-30

  Guri-Lamce et al. demonstrate efficient delivery of the adenine base editor ABE8e via lipid nanoparticles (LNPs) to correct COL7A1 mutations in fibroblasts from dystrophic epidermolysis bullosa (DEB) patients. This study highlights the potential for precise, non-viral gene editing strategies against monogenic skin disorders, with implications for future reporter gene mRNA delivery and optimization.

• Imatinib Hydrochloride: Optimizing Kinase Inhibition Workflo

  2026-04-30

  Imatinib hydrochloride (STI571 hydrochloride) delivers precise, multi-target kinase inhibition for cancer research, enabling rigorous dissection of v-Abl, c-Kit, and PDGFR signaling. Discover actionable workflow enhancements, troubleshooting strategies, and new mechanistic insights rooted in recent advances in kinase-phosphatase interplay.

• Monomethyl Auristatin E (MMAE): Precision Payload, Epigeneti

  2026-04-29

  Discover how Monomethyl auristatin E (MMAE) revolutionizes targeted cancer therapy as a next-generation ADC payload, with new insights into epigenetic plasticity and practical assay design. Explore in-depth analysis and unique perspectives beyond standard protocols.

• Substance P: Advanced Strategies for Bioaerosol Detection Re

  2026-04-29

  Explore how Substance P, a key tachykinin neuropeptide, is revolutionizing bioaerosol detection and hazardous substance classification. This in-depth article provides scientific insights, practical assay parameters, and unique guidance for researchers investigating pain, inflammation, and environmental biosurveillance.

• PPARγ Activation Modulates Macrophage Polarization in IBD Mo

  2026-04-28

  This study demonstrates that activation of PPARγ regulates M1/M2 macrophage polarization and ameliorates dextran sulfate sodium-induced inflammatory bowel disease (IBD) via modulation of the STAT-1/STAT-6 pathway. The findings provide mechanistic insights relevant to immune modulation in IBD and highlight the translational utility of PPARγ agonists in preclinical inflammatory models.

• Dissecting Drug-Induced Cell Fate: In Vitro Evaluation Advan

  2026-04-28

  Schwartz's dissertation advances cancer drug evaluation by distinguishing between proliferative arrest and cell death in in vitro assays, revealing that most anti-cancer agents induce both processes but with varying timing and magnitude. This work clarifies response metrics, informing more nuanced interpretation of tyrosine kinase inhibitor effects in oncology research.

• Olaparib (AZD2281): Applied Workflows for DNA Damage Respons

  2026-04-27

  Olaparib (AZD2281) enables precision-targeted assays in BRCA-deficient and homologous recombination-impaired cancer models. This guide translates the latest research into practical experimental workflows, troubleshooting strategies, and advanced applications for maximizing results in DNA damage response and tumor radiosensitization studies.

• CLCC1 Identified as Key Host Factor in Herpesvirus Nuclear E

  2026-04-27

  This study uncovers CLCC1 as an essential host factor mediating the membrane fusion step required for herpesvirus nuclear egress. The findings refine our understanding of herpesvirus-host interactions and suggest new experimental pathways for targeting viral replication.

• Gentamycin Sulfate: Mechanistic Leverage for Translational R

  2026-04-26

  Explore how Gentamycin Sulfate, a potent aminoglycoside antibiotic, advances translational research on Gram-negative resistance. This thought-leadership article blends mechanistic insight with strategic protocol guidance, competitive benchmarking, and a forward-looking outlook—anchored in peer-reviewed evidence and rigorous workflow recommendations.

• Baicalin: Advancing Neuroplasticity and Cancer Research Fron

  2026-04-25

  This thought-leadership article explores the dual impact of Baicalin, a flavone glycoside from Scutellaria baicalensis, on neuroplasticity and cancer workflows. By dissecting the mechanistic underpinnings—especially KEAP1-NRF2/HO-1 pathway modulation and TGF-β1/p-Smad3 pathway inhibition—we synthesize recent evidence and strategic guidance for translational researchers. Special emphasis is given to Baicalin’s role in restoring visual cortex plasticity in adult amblyopia and enhancing chemotherapeutic sensitivity in oncology models. The piece integrates key findings, protocol parameters, competitive landscape insights, and a forward-looking outlook, demonstrating how Baicalin, as supplied by APExBIO, establishes new benchmarks for reproducibility and innovation beyond standard reagent pages.

• A-1331852: Advancing Senolytic Strategies in Cancer Research

  2026-04-24

  Discover how A-1331852, a potent BCL-XL inhibitor, uniquely enables selective elimination of senescent tumor cells in advanced cancer research. This article explores deeper mechanistic insights, translational applications, and protocol guidance beyond standard apoptosis assays.

16430 records 1/1096 page Next 12345 下5页 Last page